Video

PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Kathleen N. Moore, MD, MS
Emily M. Hinchcliff, MD, MPH, an assistant professor of obstetrics and gynecology (gynecologic oncology) at the Feinberg School of Medicine at Northwestern Medicine
4 experts are featured in this series.
Stéphanie Lheureux, MD, PhD, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre
4 experts are featured in this series.
Related Content
SON-1010 in Solid Tumors | Image Credit: © magicmine – stock.adobe.com
March 5th 2025

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Ritu Salani, MD, MBA
February 17th 2025

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Ovarian Cancer | Image Credit: © Katsyarina – stock.adobe.com
February 11th 2025

Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.
February 5th 2025

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer